XOMA Royalty (NASDAQ:XOMA) Upgraded by Wall Street Zen to "Buy" Rating

XOMA Royalty (NASDAQ:XOMA - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Saturday.

A number of other research firms have also recently weighed in on XOMA. Benchmark began coverage on shares of XOMA Royalty in a research note on Thursday, April 17th. They set a "buy" rating and a $35.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $104.00 price objective on shares of XOMA Royalty in a research report on Wednesday, May 28th.

XOMA Royalty Stock Up 0.1%

XOMA stock opened at $25.83 on Friday. The business's 50-day moving average price is $25.73 and its 200-day moving average price is $24.24. The stock has a market cap of $309.19 million, a P/E ratio of -22.46 and a beta of 0.93. The company has a quick ratio of 5.54, a current ratio of 5.54 and a debt-to-equity ratio of 1.18. XOMA Royalty has a twelve month low of $18.35 and a twelve month high of $35.00.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.32. The company had revenue of $15.91 million for the quarter, compared to analysts' expectations of $6.75 million. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. On average, equities research analysts forecast that XOMA Royalty will post -1.41 EPS for the current year.

Insider Activity at XOMA Royalty

In other XOMA Royalty news, CEO Owen Hughes sold 25,637 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total value of $650,667.06. Following the sale, the chief executive officer owned 62,701 shares in the company, valued at $1,591,351.38. The trade was a 29.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $27.10, for a total transaction of $10,642,793.30. Following the transaction, the insider directly owned 1,267,545 shares of the company's stock, valued at $34,350,469.50. This trade represents a 23.65% decrease in their position. The disclosure for this sale can be found here. Company insiders own 9.10% of the company's stock.

Institutional Investors Weigh In On XOMA Royalty

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in XOMA Royalty by 1,063.8% during the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after buying an additional 1,585 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of XOMA Royalty by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock worth $113,000 after acquiring an additional 1,183 shares in the last quarter. Deutsche Bank AG boosted its position in shares of XOMA Royalty by 5,087.9% during the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 6,309 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of XOMA Royalty by 34.7% in the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock valued at $205,000 after purchasing an additional 2,009 shares in the last quarter. Finally, Nuveen LLC bought a new stake in XOMA Royalty in the first quarter worth $286,000. 95.92% of the stock is owned by institutional investors.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.